

# Synthetic Cannabinoids, Substituted Cathinones, and Other Novel Psychoactive Substances Bill Status Report – 2015

#### Research current through December 11, 2015.

This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

	Bills	
Bill No.	Description	Status and Date of Last Action
US HR 3537	Amends 21 USC 812, list of Schedule I substances, to add phenylalkylamines, with extensive list of examples; arylcyclohexamines, with extensive list of examples; tryptamines, with extensive list of examples; benzylpiperidines, with list of examples; benzodiazepines, with list of examples; opioids and opioid-like substances, with extensive list of examples; piperazines, with extensive list of examples; tropane alkaloids, with list of examples	11/17/2015 – Committee consideration and mark-up session held
AZ HB 2139	Amends § 36-2512, list of Schedule I substances, to include 2C-B, DOET, 2C-T-7, 5-MeO-DMT, AMT, 5-MeO-DiPT, mephedrone, MDPV, 2C-E, 2C-D, 2C-C, 2C-I, 2C-T-2, 2C-T-4, 2C-H, 2C-N, 2C-P, methylone, 25I-NBOMe, 25C-NBOMe, 25B-NBOMe, HU-210, APINACA, PB-22, 5F-PB-22, AB-FUBINACA, ADB-PINACA, pentedrone, BZP, 3-FMC, 4-FMC, 4-MePPP, 4-MEC, naphyrone, NN-DMA	3/17/2015 – Signed by Governor; effective July 3, 2015
CA SB 139	- Repeals and reenacts Health & Safety Code § 11357.5 to provide criminal penalties for the sale, distribution, dispensing, furnishing, administering, giving, or possession of synthetic cannabinoid compounds or synthetic cannabinoid derivatives - Defines "synthetic cannabinoid compound" to mean any of the following substances: adamantoylindoles or adamantoylindazoles, including 2NE1, 5F-AKB-48, AB-001, AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135; Benzoylindoles, including AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4, WIN 48,098; Cyclohexylphenols, including CP 47,497, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol; Cyclopropanoylindoles; Naphthoylindoles, with extensive list of examples; Naphthoylpyrroles, with extensive list of examples; Naphthoylpyrroles, with extensive list of examples; Naphthylmethylindenes, including JWH-171, JWH-176, JWH-220; Naphthylmethylindoles, including JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199; Phenylacetylindoles, with an extensive list of examples; Quinolinylindolecarboxylates, including BB-22, 5-fluoro-	9/1/2015 – In Assembly, read first time; held at desk

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	PB-22, PB-22; Tetramethylcyclopropanoylindoles,	
	including 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-	
	UR-144, A-796,260, A-834,735, AB-034, UR-144,	
	XLR11; Tetramethylcyclopropane-thiazole carboxamides,	
	including A-836,339; unclassified synthetics including:	
	AM-087, AM-356, AM-411, AM-855, AM-905, AM-906,	
	AM-2389, BAY 38-7271, CP 50,556-1, HU-210, HU-211,	
	HU-243, HU-308, HU-331, HU-336, JTE-907, JWH-051,	
	JWH-057, JWH-133, JWH-359, URB-597, URB-602,	
	URB-754, URB-937, WIN 55,212-2	
CA SB 202	Amends Civil Code § 1770 to provide that advertising,	3/18/2015 -
CA 3D 202	1	
	distributing, or selling a product for use by a consumer that	Re-referred to
	contains synthetic cannabinoids or synthetic stimulants is	Committee on
DG15 105	an unlawful deceptive act or practice	Judiciary
DC LB 485	- Amends § 48-902.04, list of Schedule I substances, to	12/1/2015 –
(B21-0485)	include the following: 25I-NBOMe, 25B-NBOMe, 25C-	Referred to
	NBOMe, 5-APB, 5-APDB, 6-APB, 6-APDB, 3-methoxy-	Committee on
	PCE, 3-methoxy-PCP, 4-methoxy-PCP, 5-MeO-DALT, 4-	Judiciary
	AcO-DMT, MXE	
	- Further amends § 48-902.04 to include definition of	
	"synthetic cathinones," which means any compound,	
	material, mixture, or preparation not otherwise listed as a	
	controlled substance in Schedules I – V, not approved by	
	the FDA, and contains any of the following: three class	
	definitions for cathinones, butylone, pentylone, naphyrone,	
	methylbuphedrone, pentedrone, 3-FMC, 3,4-DMMC, 3-	
	MEC, 3-MMC, 4-EMC, 4-MEC, 4-MePPP, 4-MeMABP,	
	4-FMC, 4-MeBP, a-ET, AMT, a-PBP, a-PVP, aminorex,	
	buphedrone, ethylcathinone, ethylone, fenethylline, FMC,	
	MDPBP, MDPPP, MDPV, 4-MMC, methcathinone,	
	methedrone, methylone, BZP, n-ethylamphetamine, N-	
	hydroxy-MDA, N,N-DMA, naphthylpyrovalerone, a-PHP,	
	N,N-dimethyl-3',4'-methylenedioxycathinone	
	- Further amends § 48-902.04 to include synthetic	
	cannabimimetic agents, which includes: class definitions	
	for adamantanoylindoles; adamantoylindoles or	
	adamantoylindazoles, including 2NE1, 5F-AKB-48, AB-	
	001, APINACA, AKB-48, JWH-018 adamantyl	
	carboxamide, STS-135; adamantylamidoindoles;	
	adamantylindazoles; adamantylindoles; benzimidazole	
	ketone, including JWH-018 benzimidazole analog,	
	FUBIMINA; benzoylindoles, including AM-630, AM-661,	
	AM-679, AM-694, AM-1241, AM-2233, RCS-4, WIN	
	AIVI-0/7, AIVI-074, AIVI-1241, AIVI-2233, KCS-4, WIN	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

48,098; carbazole ketone, including EG-018; carbozamideindazoles; cycloalkanemethanone indoles; cyclohexylphenols, including CP 47,497, CP 47,497 C8 homologue, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol; cyclopropanoylindoles; cyclopropoylindoles, including UR-144, 5C1-UR-144, XLR-11; hexahydrodibenzopyrans; hydroxycyclohexylphenol, including CP-47,497 (and homologues or analogs), cannabicyclohexanol, and CP-55,940; indole amides, including 2NE1, STS-135, ADBICA, 5F-ADBICA, NNE1, 5F-NNE1, SDB-006, 5F-SDB-006; indole esters, including PB-22, 5F-PB-22, BB-22, FDU-PB-22, NM2201; naphthoylindoles, with extensive list of examples; naphthoylnaphthalenes, including CB-13; naphthoylpyrroles, with extensive list of examples; naphthylamidoindoles; naphthylideneindenes, including JWH-176; naphthylmethane, including JWH-175, JWH-184; naphthylmethylindenes, including JWH-171, JWH-176, JWH-220; naphthylmethylindoles, including JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199; phenylacetylindoles, with extensive list of examples; quinolinoyl pyrazoles; Quinolinyl ester indoles; quinolinylindolecarboxylates, including BB-22, 5-fluoro-BB-22, PB-22; tetrahydrobenzochromen; tetrahydrocannabinols, including HU-210, JWH-051, JWH-133; tetrahydrodibenzopyrans; tetramethylcyclopropanoyl indoles, including 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, XLR11; tetramethylcyclopropane-thiazole carboxamides, including A-836,339; tetramethylcyclopropyl thiazoles; and the following unclassified synthetic cannabimimetic agents: AM-087, AM-356, AM-411, AM-855, AM-905, AM-906, AM-2389, BAY38-7271, CP 50,556-1, HU-210, HU-211, HU-243, HU-308, HU-331, JTE-907, JWH-051, JWH-057, JWH-133, JWH-359, URB-597, URB-602, URB-754, URB-937, WIN 55,212-2, AM-2201, AM-694, PB-22, 5F-PB-22, AB-FUBINACA, ADB-PINACA, MAB-CHMINACA, AB-CHMINACA, ADB-006, AM-2201 benzimidazole analog, Mepirapim, ADB-FUBINACA, 5F-ADBICA, 5F-ADB-PINACA, ADBICA, 5F-AB-PINACA, 5F-ABICA, AB-PINACA, FDU-PB-22, NM2201, THJ-

Yellow highlighted text indicates the legislation has been enacted into law

	2201, AKB48, THJ-018, FUB-PB-22, 5F-AKB48, EG- 018, FUB-144	
FL HB 73	Amends § 893.03, list of Schedule I substances, to include Kratom	9/10/2015 – Referred to various committees
FL HB 287	Amends § 893.03, list of Schedule I substances, to include Kratom	4/28/2015 – Died in Justice Appropriations subcommittee
FL HB 897	Amends § 893.03, list of Schedule I substances, to include AB-CHMINACA, FUB-PB-22, fluoro-NNE1, 5-fluoro-AMB, THJ-2201	5/14/2015 – Approved by Governor; effective on signing
FL SB 764	Amends § 893.03, list of Schedule I substances, to include Kratom	5/1/2015 – Died in Appropriations subcommittee on Health and Human Services
FL SB 1098	Amends § 893.03, list of Schedule I substances, to include AB-CHMINACA, FUB-PB-22, fluoro-NNE1, 5-fluoro-AMB, THJ-2201	4/23/2015 – Substituted by HB 897; laid on table
HI HB 856	Creates new § 321 which provides that not less than every 90 days, and in consultation with the county police departments, the department shall send written notes to the governor, the attorney general, and the legislature stating whether the department has identified any new synthetic drugs that are not currently listed; if so, the department shall immediately propose an emergency rule to add those substances as an administrative attachment to the appropriate schedule and expeditiously adopt the proposed rule; upon adoption the rule shall take effect immediately and shall sunset twelve months from the date of its adoption	1/28/2015 – Referred to various committees
HI SB 1131	- Amends § 329-14 to add ethylone to the list of substituted cathinones in Schedule I - Amends § 329-14 to add AB-CHMINACA, AB-PINACA, THJ-2201, FUB-AMB, 5-fluoro-AMB, 5F-APINACA, STS-135, NM2201 to the list of cannabinoids in Schedule I	7/2/2015 – Approved by Governor; effective on signing

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

IL HB 1497	Amends 720 § 570/204, list of Schedule I substances, to	3/27/2015 -
	include a-PVP	Re-referred to
	merade u i vi	Rules Committee
IL HB 3588	- Creates the Synthetic Drug Identification Pilot Program	4/24/2015 –
1L 11D 3300	Act which provides: 1) at least every 90 days, in	Re-referred to
	consultation with the Division of Forensic Services of the	Rules Committee
	Department of State Police, the Department of Human	Ruics Committee
	Services shall submit a report to the governor, attorney	
	general, and legislature outlining whether any new	
	chemical formulas that are used to make synthetic	
	cannabinoids or cathinones that are not currently scheduled	
	under state law have been identified; 2) if the report	
	confirms new chemical formulas have been identified, the	
	board shall as soon as practicable propose an emergency	
	rule to add any new chemical formulas and adopt the	
	proposed rule as quickly as allowed; if the board votes to	
	adopt the emergency rule, the rule will have the effect of	
	law; 3) any emergency rules adopted will automatically	
	sunset 12 months from the effective date or when the	
	legislature takes action to ratify, change, or reject the	
	emergency rule	
	- Amends 720 § 570/204 to provide that any synthetic drug	
	added to the list of Schedule I drugs by emergency rule as	
	described above shall be automatically added as a Schedule	
	I substance upon the effective date of the emergency rule	
IL HB 3660	Creates 720 § 570/201.5 which provides: 1) at least every	4/24/2015 —
	90 days, in consultation with the Division of Forensic	Re-referred to
	Services of the Department of State Police, the Department	Rules Committee
	of Human Services shall submit a report to the governor,	
	attorney general, and legislature outlining whether any new	
	chemical formulas that are used to make synthetic	
	cannabinoids or cathinones that are not currently scheduled	
	under state law have been identified; 2) if the report	
	confirms new chemical formulas have been identified, the	
	board shall immediately propose an emergency rule to add	
	any new chemical formulas and adopt the proposed rule as	
	quickly as allowed; if the board votes to adopt the	
	emergency rule, the rule will have the effect of law; 3) any	
	emergency rules adopted will automatically sunset 12	
	months from the effective date or when the legislature	
	takes action to ratify, change, or reject the emergency rule	

		_
IL SB 206	- Amends 720 § 570/102, definitions, to include synthetic drugs or a class of synthetic drug in the definition of "controlled substance" - Further amends 720 § 570/102 to include a definition for "synthetic drug" which means any synthetic cannabinoids, piperazines, or cathinones, identified either by a specific chemical configuration or as belonging to a specific structural class - Creates 720 § 570/201.1 which provides that the department may, by rule, identify certain classes of synthetic drugs and schedule them according to the schedule of controlled substance or substances they encompass - in making the determination of whether to schedule a class of synthetic drugs, the department shall consider: 1) the structural similarity between the chemical configuration of synthetic drugs and their analogs and their ability to be classified based on their shared structure; 2) the degree of danger or probable danger of the chemical compounds that the class would encompass; 3) the substantial similarity between the synthetic drugs encompassed by the proposed class and the controlled substance or substances they mimic by comparing any or all of the following: a) the chemical structure; b) their stimulant, depressant, or hallucinogenic effect on the central nervous system; c) the similarity of their effects on particular receptors; d) the degree to which the proposed class of substances mimics the pharmacological, physiological, or psychological effect of a controlled substance; or e) the ability of manufacturers to circumvent statutory criteria by merely manipulating the chemical structure in endless variations with the pharmacological effect remaining substantially unchanged; 4) the extent to which the substances at issue are implicitly intended for human consumption; and 6) any misleading importation, manufacture, distribution, labeling, or advertising of products containing substances that would	4/24/2015 — Passed Senate; referred House Rules Committee
IL SB 1129	advertising of products containing substances that would be included in the proposed class	8/14/2015 —
IL SD 1129	<ul> <li>Amends 720 § 570/102, definitions, to include synthetic drugs in the definition of "controlled substance"</li> <li>Amends 720 § 570/204, list of Schedule I substances, to add TFMPP, amends class definitions and adds examples,</li> </ul>	Approved by Governor; effective 1/1/2016

	including: JWH-018, AM-2201, JWH-175, JWH-184,	
	JWH-185, JWH-030, JWH-145, JWH-146, JWH-307,	
	JWH-368, JWH-176, JWH-167, JWH-250, JWH-251,	
	RCS-8, CP 47,497, cannabicyclohexanol; benzoylindoles,	
	which includes, AM-630, AM-2233, AM-694, WIN	
	48,098, RCS-4; XLR-11, UR-144, FUB-144, AB-001,	
	APICA/2NE-1, STS-135, AKB-48, 5F-AKB-48, PB-22,	
	5F-PB-22, FUB-PB-22, THJ-018, THJ-2201, FUBIMINA,	
	AB-PINACA, AB-FUBINACA, AB-CHMINACA, ADB-	
	PINACA, ADB-FUBINACA, ADBICA, 5F-ADBICA,	
	ABICA, 5F-ABICA, AMB, 5F-AMB; synthetic cathinones	
	class definition, which includes bk-MDA, buphedrone,	
	dimethylcathinone, ethcathinone, a-PPP	
IL SB 1282	- Amends 720 § 570/102, definitions, to include a	10/10/2015 -
	definition for "synthetic drug" which includes any	Senate committee
	synthetic cannabinoids or piperazines or any synthetic	Amendment 1,
	cathinones	referred to
	- Amends 720 § 570/204, list of Schedule I substances, to	Assignments
	include synthetic cannabinoids or piperazines, which	8
	includes: BZP, TFMPP, HU-210, JWH-073, HU-211, and	
	any compound in the following structural classes:	
	naphthylmethylindoles, including JWH-175, JWH-184,	
	JWH-185; phenylacetylindoles, including JWH-167, JWH-	
	250, JWH-251, RCS-8; benzoylindoles, including AM-	
	630, AM-2233, AM-694, WIN 48,098, RCS-4;	
	cyclohexylphenols, including CP 47,497,	
	cannabicyclohexanol; naphthylmethylindoles, including	
	JWH-175, JWH-184, JWH-185; naphthoylpyrroles,	
	including JWH-030, JWH-145, JWH-146, JWH-307,	
	JWH-368; naphthylmethylindenes, including JWH-276	
	- Amends 720 § 204, list of Schedule I substances, to	
	include synthetic cathinones with the class definition and	
	specific substances including: bk-MDA, buphedrone,	
	dimethylcathinone, ethcathinone, a-PPP	
	AMENDMENT 1 – substitutes the language of SB 1129	
IA HF 567	Amends § 124.204, list of Schedule I substances, to add: 5-	5/7/2015 –
IA III JU	MeO-DMT; 2C-E; 2C-D; 2C-C; 2C-I; 2C-T-2; 2C-T-4;	Senate
	2C-H; 2C-N; 2C-P; methylone; 4-MEC; 4-MePPP;	amendment filed
	pentedrone; pentylone; a-PBP; HU-210; HU-211;	amenument meu
	definition for "cannabimimetic agents" which includes	
	class definitions and the following substances: CP 47,497,	
	JWH-018, JWH-073, JWH-200, JWH-019, JWH-081,	
	JWH-122, JWH-250, RCS-4, RCS-8, AM-2201, JWH-203,	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	WIII 200 AM 604 compakies-1-11. AD	
	JWH-398, AM-694, cannabicyclohexanol; AB-	
	FUBINACA; ADB-PINACA; PB-22; 5-fluoro-PB-22; AB-	
	PINACA; AB-CHMINACA; THJ-2201;	
IA LD 1218	Amends § 124.204, list of Schedule I substances, to add: 4-	1/2/20105 —
	MEC, 4-MePPP, a-PVP, butylone, pentedrone, pentylone,	Draft/request
	4-FMC, 3-FMC, naphyrone, a-PBP, PB-22, 5-fluoro-PB-	
	22, AB-FUBINACA, ADB-PINACA	
IA SF 320	- Creates new § 613.15B that includes definitions for	2/26/2015 -
	"distributor" (a person who sells synthetic cannabinoids to	Referred to
	another person) and "synthetic cannabinoid" (any	subcommittee
	compound targeted to the cannabinoid receptor that is not	
	marijuana or tetrahydrocannabinol or any other	
	cannabinoid naturally contained in the plan of the genus	
	cannabis) and provides that if the consumption of a	
	synthetic cannabinoid is the proximate cause of a person's	
	suicide or attempted suicide, the distributor and	
	manufacturer of the synthetic cannabinoid shall each be	
	strictly liable for the damages	
KS HB 2275	Amends § 65-4105, list of Schedule I substances, to	4/29/2015 -
	include 25D-NBOMe; amends class definitions for	Approved by
	synthetic cannabinoids; and adds new class definition for	Governor;
	(1H-idazol-3-yl)methanones	effective
	(111 Idazor 3 yr)methanones	4/16/2015
<b>LA HB 72</b>	Amends § 40:964, list of Schedule I substances, to add 2C-	7/1/2015 –
	B; 25B-NBOMe; 5-MAPB; 4-hydroxy-MIPT; a-PBT; a-	Signed by
	PVT; amends class definitions; adds the following class	Governor;
	definitions: naphthylindolecarboxylates,	effective 7/1/2015
	benzylindolecarboxamides, quinolinylindolecarboxamides,	effective 7/1/2013
	phenylindolecarboxamides, butaldehydeamidoindoles,	
	phenylpropionaldehydeamidoindoles,	
	cumylindolecarboxamides; 5F-PCN; UR-12; EG-018; BB-	
	22; naphthalen-1-yl(9-(5-fluoropentyl)-9H-carbazol-3-	
MD IID	yl)methanone	2/24/2015
MD HB	- Amends Criminal Law § 5-101 to amend the definition of	3/24/2015 —
1057	"synthetic cannabinoid" to mean a synthetic chemical	Hearing
	compound that is a cannabinoid receptor agonist and that	scheduled
	mimics the pharmacological effect of a naturally occurring	
	cannabinoid or a controlled substance listed in Schedule I	
	or II	
	- "Synthetic cannabinoid" includes a substance or analog	
1	of a substance that is designed, generated, or recombined	
	to create a new structure using a three-component pharmacophore model and that contains one or more	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

		1
	pharmacophores or components of a controlled substance listed in Schedule I or II	
	- Amends Criminal Law § 5-402, list of Schedule I	
	substances, to include synthetic cannabnoids	
MA HB	Amends 94C § 31, list of Class A substances, to add class	7/14/2015 –
1478	definitions	Hearing
14/0	definitions	rescheduled
MN HF 849	Amends § 152.02, list of Schedule I substances, to add	4/25/2015 –
WIN DF 649	25B-NBOMe, 25C-NBOMe, 2C-H, 2C-T-2, 3-FMC,	Indefinitely
	naphyrone, butylone, a-PVP, a-PHP, 4-MEC, 4-MePPP,	•
		postponed
	pentedrone, pentylone, 4-FMC, ethylone, a-PBP, 5-APDB,	
	6-APDB, AB-CHMINACA, 5-fluoro-AMB, THJ-2201,	
	FUBIMINA, MN-25, 5-fluoro-ABICA, N-(1-amino-3-	
	phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-	
	3-carboxamide, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-	
	1-(5-fluoropentyl) -1H-indazole-3-carboxamide, methyl 2-	
	(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-	
1077777	dimethylbutanoate	1/20/2015
MN HF 1376	Amends § 152.02, list of Schedule I substances, to add	4/30/2015 –
	25B-NBOMe, 25C-NBOMe, 2C-H, 2C-T-2, 3-FMC,	Indefinitely
	naphyrone, butylone, a-PVP, a-PHP, 4-MEC, 4-MePPP,	postponed
	pentedrone, pentylone, 4-FMC, ethylone, a-PBP, 5-APDB,	
	6-APDB, AB-CHMINACA, 5-fluoro-AMB, THJ-2201,	
	FUBIMINA, MN-25, 5-fluoro-ABICA, N-(1-amino-3-	
	phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-	
	3-carboxamide, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-	
	1-(5-fluoropentyl) -1H-indazole-3-carboxamide, methyl 2-	
	(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-	
	dimethylbutanoate	
MN SF 878	Amends § 152.02, list of Schedule I substances, to add	<mark>5/22/2015 —</mark>
	25B-NBOMe, 25C-NBOMe, 2C-H, 2C-T-2, 3-FMC,	Approved by
	naphyrone, butylone, a-PVP, a-PHP, 4-MEC, 4-MePPP,	Governor;
	pentedrone, pentylone, 4-FMC, ethylone, a-PBP, 5-APDB	effective 7/1/2015
	6-APDB, AB-CHMINACA, 5-fluoro-AMB, THJ-2201,	
	FUBIMINA, MN-25, 5-fluoro-ABICA, N-(1-amino-3-	
	phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-	
	3-carboxamide, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-	
	1-(5-fluoropentyl) -1H-indazole-3-carboxamide, methyl 2-	
	(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-	
	dimethylbutanoate	
MN SF 1219	Amends § 152.02, list of Schedule I substances, to add	4/30/2015 -
	25B-NBOMe, 25C-NBOMe, 2C-H, 2C-T-2, 3-FMC,	Second reading in
	naphyrone, butylone, a-PVP, a-PHP, 4-MEC, 4-MePPP,	House
	maprigrone, outgrone, a r vr, a r m, + mile, + mer r,	110050

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	pentedrone, pentylone, 4-FMC, ethylone, a-PBP, 5-APDB 6-APDB, AB-CHMINACA, 5-fluoro-AMB, THJ-2201,	
	FUBIMINA, MN-25, 5-fluoro-ABICA, N-(1-amino-3-	
	phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-	
	3-carboxamide, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-	
	1-(5-fluoropentyl) -1H-indazole-3-carboxamide, methyl 2-	
	(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-	
	dimethylbutanoate	
MS HB 241	Amends § 41-29-113 to include derivatives of synthetic	2/3/2015 —
	cannabinoids to the description of synthetic cannabinoids	Died in
	in Schedule I, and includes any synthetic cannabinoid	committee
	included in any package or product that reads "not for	
	human consumption" or marketed as potpourri or incense	
MS HB 1332	Amends § 41-29-113 to add synthetic cathinones to the list	2/3/2015 —
	of Schedule I substances, including: 4-MEC, 4-MePPP, a-	Died in
	PVP, butylone, pentedrone, pentylone, 4-FMC, 3-FMC,	committee
	naphyrone, a-PBP	
MS SB 2118	Amends § 41-29-113 to add synthetic cathinones to the list	3/30/2015 —
	of Schedule I substances, including: 4-MEC, 4-MePPP, a-	Died in
	PVP, butylone, pentedrone, pentylone, 4-FMC, 3-FMC,	conference
	naphyrone, a-PBP	
NE LB 189	- Amends § 28-401, definitions, to add definitions for: 1)	2/20/2015 —
	"cannabinoid receptor agonist," which means any chemical	Judiciary
	compound or substance that, according to scientific or	amendment filed
	medical research, study, testing, or analysis, demonstrates	
	the presence of binding activity at one or more of the CB1	
	or CB2 cell mebrane receptors; 2) "controlled substance	
	analogue," which means a substance a) the chemical	
	structure of which is substantially similar to the chemical	
	structure of a Schedule I or II substance or b) which has a	
	stimulant, depressant, analgesic, or hallucinogenic effect	
	on the central nervous system of a Schedule I or II	
	substance; shall be treated as a Schedule I substance;	
	includes exceptions	
	- Amends § 28-405, list of Schedule I substances, to amend	
	the definition of "synthetic tetrahydrocannabinols" to mean	
	any equivalent of the substances naturally contained in a	
	plant of the genus cannabis or derivatives and their isomers	
	with similar chemical structure and pharmacological	
	activity	
NE LB 326	- Amends § 28-405, list of Schedule I substances, to amend	5/29/2015 —
	the class definitions under synthetically produced	Indefinitely
	j i i i i i i i i i i i i i i i i i i i	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

NV SB 234	- Amends § 453.146 to provide that the board shall, by extraordinary regulation, designate as a Schedule I controlled substance any chemical compound that is chemically synthesized and has been demonstrated to have binding activity at one or more cannabinoid receptors or is substantially similar to, or is an isomer of, a chemical compound that has been demonstrated to have binding activity at one or more cannabinoid receptors	4/11/2015 – Pursuant to Joint Standing Rule 14.3.1, no further action allowed
NH SB 106	- Creates § 179:63 to provide that any licensee authorized to sell alcoholic beverages who sells or distributes any synthetic drug is guilty of a violation  - Amends §§ 284:21-h and 143-A:9-b to provide that any owner of a retail establishment or sale outlet or any food service licensee who sells or distributes any substance containing a synthetic drug is guilty of a violation  - Creates Chapter 359-O which provides penalties for persons or businesses who sell, barter, give, publicly display for sale, or attempt to sell, or to possess or transport any material, compound, mixture, or preparation which contains any quantity of a synthetic drug  - Includes definition of "synthetic drug" which means any substance within the following structural classes: cyclohexylphenols; naphthylmethylindenes; any compound containing an indole ring system or pyrrole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the indole ring system or pyrrole ring system or pyrazole ring system with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the indazole ring system or pyrazole ring system; any compound containing an aphthalene ring system with a substituent on the 1-position carbon atom and bearing an additional substituent at the 4-position of the naphthalene ring system; any compound containing a carbazole ring system with a substituent on the 1-position carbon atom and bearing an additional substituent at the 1, 2, or 3-position of the carbazole ring system; any compound containing a carbazole ring system with a substituent at the 1, 2, or 3-position of the carbazole ring system; any substance which includes, but is not limited to, QUCHIC/BB-22, STS-135, APICA/SDB-001, ADBICA, AB-PINACA, ADB-FUBINACA, AB-CHMINACA, AB-O01, SDB-006, EG-018, CB-13, 5-chloro-UR-144, FUB-PB-22; any synthetic cathinones, defined as any of the following chemical structures, their salts, isomers, and salts	7/7/2015 – Signed by Governor; effective 7/6/2015

		T
	of isomers: 3,4-DMMC, eutylone, ethylone, methedrone,	
	and class definition; any synthetic psychoactive compound	
	or substance within the following specific chemical	
	designation: 25D-NBOMe, 25E-NBOMe, 25N-NBOMe,	
	25P-NBOMe, 25T2-NBOMe, 25T4-NBOMe, 25T7-	
	NBOMe, 34-DMA-NBOMe, 2-APB, 5-APDB, 2-EAPB,	
	5-MAPB, 3,4-CTMP, 5,6-MDAI, 4-hydroxy-DET,	
	methoxydine, AH-7921, BTCP, MXE, CL218872,	
	diphenidine, MT-45, nitrocaine, W-15, W-18, 4-FA,	
	methiopropamine	
NJ AB 4456	Amends §§ 2C:35-5.3a and 2C:35-10.3a to add a-PVP	6/1/2015 -
NJ AD 4430	Amends §§ 20.33-3.3a and 20.33-10.3a to add a-1 v1	Introduced,
		,
		referred to
111 GD 2002	1 20 20 27 20 120 27 10 2	committee
NJ SB 3003	Amends §§ 2C:35-5.3a and 2C:35-10.3a to add a-PVP	6/11/2015 –
		Introduced;
		referred to
		committee
NY AB 1910	Amends Public Health Law § 3306, list of Schedule I	6/17/2015 —
	substances, to add synthetic cannabinoids as follows:	Passed Assembly;
	naphthoylindoles, which includes JWH-015, JWH-018,	referred to Senate
	JWH-019, JWH-073, JWH-081, JWH-122, JWH-200,	Rules committee
	JWH-210, JWH-398, AM-2201, WIN 55212;	
	naphthylmethylindoles, which includes JWH-175, JWH-	
	184; naphthoylpyrroles, which includes JWH-307;	
	naphthylmethylindenes, which includes JWH-176;	
	phenylacetylindoles, which includes RCS-8, JWH-250,	
	JWH-203, JWH-251, JWH-302; cyclohexylphenols, which	
	includes CP 47,497, cannabicyclohexanol, CP 55,940;	
	benzoylindoles, which includes AM-694, WIN 48,098,	
	RCS-4, AM-679; adamantoylindoles, which includes AM-	
377 45 4455	1248; WIN 55,212-2; HU-210; HU-211; UR-144	1 /20 /2017
NY AB 4175	- Creates § 220.66 which criminalizes the sale, use, or	1/29/2015 –
	possession of synthetic drugs or other similar compounds	Referred to Codes
	- Includes definition of "synthetic drug" which means any	
	product, whether described as tobacco, potpourri, herbs,	
	incense, spice, aromatic bath salts, synthetic marijuana,	
	synthetic stimulant, or any combination thereof, and	
	whether marketed for the purpose of being ingested or not,	
	and includes, but is not limited to: 1) synthetic	
	cannabinoids – those substances that are a cannabinoid	
	type 1 receptor as demonstrated by binding studies and	
	function assays or is a structural analog or chemical	
L	1	l .

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	derivative of one of 17 listed chemical compounds; 2)	
	synthetic cathinones – those substances that are structural	
	analogs of cathinone, including any chemical derivatives of	
	cathinone which by definition has a structural substitution	
	on the benzene ring or aliphatic chain or contains a	
	structural analog or chemical derivative of any of the	
	following listed chemicals: methadrone, 3-FMC, 4-FMC,	
	2-MMC, 3-MMC, 2-EEC, 3-EEC, 4-EEC, 2-MEC, 3-	
	MEC, 4-MEC, 4-FEC, EMC, pentylone, pentedrone, a-	
	PVP, ethylone, a-PPP, MDPPP, naphyrone; 3) substituted	
	phenethylamines – those substances that are structural	
	analogs of any phenethylamine scheduled under state law,	
	including any chemical derivatives of scheduled	
	phenethylamines which by definition has a structural	
	substitution on the benzene ring or aliphatic chain or	
	contains a structural analog of any of the following listed	
	compounds: 4-MA, 3-MA, 4-CA, 4-FA, 25I-NBOMe,	
	25C-NBOMe, or 1-(6-benzofuranyl)-2-propanamine; 4)	
	substituted phenylpiperazines – those substances that are	
	chemical analogs of benzylpiperazine or any chemical	
	derivatives of benzylpiperazine which by definition has a	
	, <u>, , , , , , , , , , , , , , , , , , </u>	
	structural substitution on the benzene or piperazine ring or	
	contains a structural analog of any of the following listed	
	compounds: TFMPP, mCPP, pCPP, pFPP, 4-MeOPP,	
	DBZP; 5) substituted tryptamines – those substances that	
	are structural analogs of dimethyltryptamine or psilocin or	
	any chemical derivative of dimethyltryptamine which by	
	definition has a structural substitution on the indole ring or	
	aliphatic chain or contains a structural analog of 5-MeO-	
	DALT; 6) the following unclassified substances: 2-DPMP,	
	3-MeO-PCP, 4-MeO-PCP, MXE, demthocaine, MDAI, 5-	
	IAI; 7) any substance that includes toxic effects including	
	but not limited to vomiting, rapid heart rate, hallucinations,	
	delusions and/or babbling	
	- Includes definitions of "structural analog," "chemical	
	derivative," "element," and "chemical group"	
NY AB 4579	- Amends Public Health Law § 3302 to add definition for	2/3/2015 —
	"synthetic cannabinoid" which means any material,	Referred to
	compound, mixture, or preparation containing any quantity	Health
	of the following: CP 47,497, HU-210, HU-211, JWH-018,	
	JWH-073	

	- Amends Public Health Law § 3306, list of Schedule I substances, to include CP 47,497, HU-210, HU-211, JWH-073, JWH-018 - Amends Public Health Law § 3308 to provide that the commissioner, in conjunction with the division of criminal justice systems, shall establish and maintain a database of known synthetic cannabinoids that shall be published on the department's website	
NY AB 5453	- Amends Public Health Law § 3302 to add definition for "synthetic cannabinoid" which means any chemical compound that is chemically synthesized and has been demonstrated to have a binding activity at one or more cannabinoid receptors or is a chemical isomer, salt, or salt of an isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors - Further amends Public Health Law § 3302 to add definition for "synthetic cannabinoid analog" which means any chemical that is substantially similar in chemical structure to a chemical compound that has been determined to have binding activity at one or more cannabinoid receptors	2/23/2015 – Referred to Health
NY AB 8409	Amends Penal Law § 220.00 to include a definition for "synthetic cannabinoid" which means any chemical compound that is a cannabinoid receptor and includes, but is not limited to, any material, compound, mixture, or preparation that is not listed as a controlled substance, and includes penalties for sale of synthetic cannabinoids	10/9/2015 – Referred to Codes
NY AB 8441	- Creates General Business Law § 399-hh which provides that no person, firm, corporation, partnership, association, LLC, or other entity shall sell, offer for sale, distribute, or give away, for retail, wholesale, or promotional purposes any synthetic cannabinoid - Provides for fines for the first two violations in a five year period and on a third violation, the court shall provide notice to the commissioner of taxation and finance, the division of lottery, and the state liquor authority and the violator shall be prohibited from selling cigarettes and tobacco products, lottery tickets, and alcoholic beverages for a period of five years - Amends Tax Law §§ 480 and 1607 to provide that three or more violations of the above statute within any five year period shall result in the suspension of the violator's license for a period of five years	10/9/2015 – Referred to economic development

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

NY SB 2836	- Amends Public Health Law § 3302 to add a definition for "synthetic cannabinoid" which means any chemical compound that is a cannabinoid receptor agonist and includes, but is not limited to, any material, compound, mixture, or preparation that is not approved by the FDA, and contains any of the following substances, their salts, isomers, homologues (analogs), and salts of isomers and homologues (analogs): tetrahydrocannabinols, naphthoylindoles, naphthylmethylindoles, naphthylideneindenes, phenylacetylindoles, cyclohexylphenols, benzoylindoles, or adamantoylindoles; HU-210; HU-211; WIN-55,212-2 - Amends Public Health Law § 3306, list of Schedule I substances, to add class definitions for naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylideneindenes, phenylacetylindoles, cyclohexylphenols, benzoylindoles, or adamantoylindoles and the following specific substances: HU-210, HU-211, WIN 55,212-2 - Further amends § 3306 to add a new section requiring the commissioner, in conjunction with the division of criminal	6/17/2015 – Passed Senate; referred to House Health committee
	justice services, to establish and maintain a database of	
NY SB 4712	known synthetic cannabinoids and substituted cathinones  - Amends Public Health Law § 3302 to add definition for "synthetic cannabinoid" which means any chemical compound that is chemically synthesized and has been demonstrated to have a binding activity at one or more cannabinoid receptors or is a chemical isomer, salt, or salt of an isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors - Further amends Public Health Law § 3302 to add definition for "synthetic cannabinoid analog" which means any chemical that is substantially similar in chemical structure to a chemical compound that has been determined to have binding activity at one or more cannabinoid receptors	4/10/2015 – Referred to Health
NY SB 4720	- Amends Public Health Law § 3302 to add definitions for "synthetic cannabinoid," "synthetic cannabinoid analog," and "substituted cathinone" - "Synthetic cannabinoid" means any chemical compound that is chemically synthesized and has been demonstrated to have binding activity at one or more cannabinoid receptors or is a chemical isomer, salt or salt of an isomer	4/10/2015 – Referred to Health

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	of a compound that has been demonstrated to have binding	
	activity at one or more cannabinoid receptors	
	- "Synthetic cannabinoid analog" means any chemical that	
	is substantially similar in chemical structure to a chemical	
	compound that has been demonstrated to have binding	
	activity at one or more cannabinoid receptors	
	- "Substituted cathinone" means any chemical compound	
	that is chemically synthesized and is a compound listed in	
	§ 3306, or has been designated by regulation as having a	
	chemical structure derivative of cathinone, or any	
	compound, other than buproprion, that is structurally	
	derived from 2-amino-1-phenyl-1-propanone by	
	modification in any of the following ways: (i) by	
	substitution in the phenyl ring to any extent with alkyl,	
	alkoxy, alkylenedioxy, haloalkyl, or halide substituents,	
	whether or not further substituted in the phenyl ring by one	
	or more other univalent substituents; (ii) by substitution at	
	the three-position with an alkyl substituent; (iii) by	
	substitution at the nitrogen atom with alkyl or dialkyl	
	groups, or by inclusion of the nitrogen atom in a cyclic	
	structure	
	- Amends Penal Law § 220.00 to include substituted	
	cathinones in the definition of "controlled substance" and	
	include "synthetic cannabinoid" and "synthetic	
	cannabinoid analog" in the definition of "marihuana"	
NY SB 5888	- Creates § 220.66 which criminalizes the sale, use, or	6/17/2015 -
	possession of synthetic drugs or other similar compounds	Passed Senate;
	- Includes definition of "synthetic drug" which means any	referred to
	product, whether described as tobacco, potpourri, herbs,	Assembly Codes
	incense, spice, aromatic bath salts, synthetic marijuana,	committee
	synthetic stimulant, or any combination thereof, and	
	whether marketed for the purpose of being ingested or not,	
	and includes, but is not limited to: 1) synthetic	
	cannabinoids – those substances that are a cannabinoid	
	type 1 receptor as demonstrated by binding studies and	
	function assays or is a structural analog or chemical	
	derivative of one of 17 listed chemical compounds; 2)	
	synthetic cathinones – those substances that are structural	
	analogs of cathinone, including any chemical derivatives of	
	cathinone which by definition has a structural substitution	
	on the benzene ring or aliphatic chain or contains a	
	structural analog or chemical derivative of any of the	
	following listed chemicals: methadrone, 3-FMC, 4-FMC,	

	2-MMC, 3-MMC, 2-EEC, 3-EEC, 4-EEC, 2-MEC, 3-	
	MEC, 4-MEC, 4-FEC, EMC, pentylone, pentedrone, a-	
	PVP, ethylone, a-PPP, MDPPP, naphyrone; 3) substituted	
	phenethylamines – those substances that are structural	
	analogs of any phenethylamine scheduled under state law,	
	including any chemical derivatives of scheduled	
	phenethylamines which by definition has a structural	
	substitution on the benzene ring or aliphatic chain or	
	contains a structural analog of any of the following listed	
	compounds: 4-MA, 3-MA, 4-CA, 4-FA, 25I-NBOMe,	
	25C-NBOMe, or 1-(6-benzofuranyl)-2-propanamine; 4)	
	substituted phenylpiperazines – those substances that are	
	chemical analogs of benzylpiperazine or any chemical	
	derivatives of benzylpiperazine which by definition has a	
	structural substitution on the benzene or piperazine ring or	
	contains a structural analog of any of the following listed	
	compounds: TFMPP, mCPP, pCPP, pFPP, 4-MeOPP,	
	DBZP; 5) substituted tryptamines – those substances that	
	are structural analogs of dimethyltryptamine or psilocin or	
	any chemical derivative of dimethyltryptamine which by	
	definition has a structural substitution on the indole ring or	
	aliphatic chain or contains a structural analog of 5-MeO-	
	DALT; 6) the following unclassified substances: 2-DPMP,	
	3-MeO-PCP, 4-MeO-PCP, MXE, demthocaine, MDAI, 5-	
	IAI; 7) any substance that includes toxic effects including	
	but not limited to vomiting, rapid heart rate, hallucinations,	
	delusions and/or babbling	
	- Includes definitions of "structural analog," "chemical	
	derivative," "element," and "chemical group"	
NY SB 6039	Amends Penal Law § 220.00 to include a definition for	8/26/2015 –
2.1.2.2.3037	"synthetic cannabinoid" which means any chemical	Referred to Rules
	compound that is a cannabinoid receptor and includes, but	113101104 10 114105
	is not limited to, any material, compound, mixture, or	
	preparation that is not listed as a controlled substance, and	
	includes penalties for sale of synthetic cannabinoids	
NY SB 6040	- Creates General Business Law § 399-hh which provides	8/26/2015 –
111 52 00 10	that no person, firm, corporation, partnership, association,	Referred to Rules
	LLC, or other entity shall sell, offer for sale, distribute, or	1.0101104 10 114105
	give away, for retail, wholesale, or promotional purposes	
	any synthetic cannabinoid	
	- Provides for fines for the first two violations in a five	
	year period and on a third violation, the court shall provide	
	notice to the commissioner of taxation and finance, the	
	notice to the commissioner of taxation and imance, the	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	division of lottery, and the state liquor authority and the violator shall be prohibited from selling cigarettes and tobacco products, lottery tickets, and alcoholic beverages for a period of five years  - Amends Tax Law §§ 480 and 1607 to provide that three or more violations of the above statute within any five year period shall result in the suspension of the violator's license for a period of five years	
NC HB 341	- Amends § 90-89, list of Schedule I substances, to add: MXE, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25G-NBOMe, 25H-NBOMe, 25I-NBOMe, 25N-NBOMe, 25P-NBOMe, 25T2-NBOMe, 25T4-NBOMe, 25T7-NBOMe - Amends § 90-94, list of Schedule VI substances, to add: substances including a 3-(cyclopropylmethanone) indole, which includes UR-144, fluoro-UR-144, XLR-11, A-796,260, A-834,735; indole carboxaldehydes, which includes AB-001; indole carboxamides, which includes SDB-001, STS-135; indole carboxylic acids, which includes PB-22, fluoro-PB-22; indazole carboxaldehydes; Indazole carboxamides, which includes AKB-48, fluoro-AKB-48, APINCACA, AB-PINACA, AB-FUBINACA, ADB-FUBINACA, ADB-FUBINACA, indazole carboxylic acids	7/17/2015 – Signed by Governor; effective 12/1/2015
ND SB 2100	Amends § 19-03.1-05, list of Schedule I substances, to include: class definitions for indole carboxaldehydes, which includes JWH-018, JWH-073, JWH-081, JWH-200, JWH-015, JWH-019, JWH-122, JWH-210, JWH-398, AM-2201, RCS-8, JWH-250, JWH-251, JWH-203, RCS-4, AM-694, WIN 48,098, UR-144, XLR-11, A-796,260, THJ-2201, THJ-018, FUBIMINA, AM-1248, AB-001; indole carboxamides, which includes APICA, STS-135, AKB-48, NNEI, ADBICA, AB-PINACA, AB-FUBINACA, 5-fluoro-AB-PINACA, ADB-PINACA, AB-CHMINACA, ADB-FUBINACA, FUB-AKB48, 5-fluoro-THJ, 5-fluoro-AMB, FUB-AMB; indole carboxylic acids, which includes BB-22, FDU-PB-22, PB-22, 5-fluoro-PB-22, FUB-PB-22, NM2201	3/19/2015 – Signed by Governor; filed with Secretary of State; effective on signing
OK HB 1616	Amends 63 § 2-204, list of Schedule I substances, to add MXE, amends class definitions, and adds ADBICA, 5F-ADBICA, NNE1, 5F-NNE1, SDB-006, 5F-SDB-006; indole esters, which includes PB-22, 5F-PB-22, BB-22, FDU-PB-22, NM2201; adamantanoylindoles, which	5/12/2015 – Signed by Governor; effective 11/1/2015

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	includes AM-1248, AB-001; carbazole ketones, which	
	includes EG-018; benzimidazole ketones, which includes	
	JWH-018 benzimidazole analog, FUBIMINA	
OR HB 2033	Directs the state Board of Pharmacy to classify any	7/6/2015 –
OK IID 2033	1	In committee
	synthetically manufacture cannabinoid as a Schedule I	
	controlled substance, not including those that have been	upon adjournment
DA HD 600	approved by the FDA for a therapeutic purpose	10/14/2015
PA HB 608	- Amends 35 § 780-104, list of Schedule I substances, to	10/14/2015 –
	include: methylone; MDPV; methedrone; MXE;	Passed House; in
	substituted cathinones, with class definition; synthetic	Senate Judiciary
	cannabinoids, which includes: indole carboxaldehydes,	committee
	with an extensive list of examples; indole carboxamides,	
	including AB-CHMINACA, AB-FUBINACA, AB-	
	PINACA, ADBICA, ADB-PINACA, AKB-48, AMB,	
	NNEI, STS-135, THJ; indole carboxylic acids, which	
	includes BB-22, 3-CAF, FDU-PB-22, FUB-PB-22,	
	NM2201, PB-22; psychedelic phenethylamines, including	
	25C-NBOMe, 25I-NBOMe, 25B-NBOMe	
PA HB 1052	Provides that any synthetic cannabinoid or cathinone not	4/27/2015 —
	regulated by the FDA or by state law that binds to a	Referred to
	cannabinoid receptor or mimics the pharmacological	Judiciary
	response of a Schedule I or II substance shall be considered	
	a Schedule II substance under state law	
RI SB 507	- Amends § 21-28-2.08, list of Schedule I substances, to	3/3/2015 —
	add any synthetic cannabinoid or cathinone not regulated	Withdrawn at
	by the FDA or by state law binds to a cannabinoid receptor	sponsor's request
	and/or mimics the pharmacological response of a Schedule	
	I or II substance shall be considered a Schedule I substance	
	- Creates § 21-28-7.0 which provides that in determining	
	whether a synthetic or cathinone binds to a cannabinoid	
	receptor and/or mimics a pharmacological response, the	
	following process shall be used: 1) at least every 90 days,	
	in consultation with the state police forensic department,	
	the board of pharmacy shall send official correspondence	
	to the governor, attorney general, and legislature outlining	
	whether any new chemical formulas that are used to make	
	synthetic cannabinoids or cathinones that are not currently	
	scheduled under state law have been identified; 2) if	
	correspondence confirms new chemical formulas have	
	been identified, the board shall immediately propose an	
	emergency rule to determine and add any new chemical	
	formulas and vote on the proposed rule as quickly as	
	allowed; if the board votes to adopt the emergency rule, it	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	shall take effect immediately; 3) any emergency rules adopted will automatically sunset 12 months from the	
RI SB 509	- Amends § 21-28-2.08, list of Schedule I substances, to add any synthetic cannabinoid or cathinone not regulated by the FDA or by state law binds to a cannabinoid receptor and/or mimics the pharmacological response of a Schedule I or II substance shall be considered a Schedule I substance - Creates § 21-28-7.0 which provides that in determining whether a synthetic or cathinone binds to a cannabinoid receptor and/or mimics a pharmacological response, the following process shall be used: 1) at least every 90 days, in consultation with the state police forensic department, the board of pharmacy shall send official correspondence to the governor, attorney general, and legislature outlining whether any new chemical formulas that are used to make synthetic cannabinoids or cathinones that are not currently scheduled under state law have been identified; 2) if correspondence confirms new chemical formulas have been identified, the board shall immediately propose an emergency rule to determine and add any new chemical formulas and vote on the proposed rule as quickly as allowed; if the board votes to adopt the emergency rule, it shall take effect immediately; 3) any emergency rules adopted will automatically sunset 12 months from the effective date	3/3/2015 – Committee recommended measure be held for further study
SC HB 4122	- Amends § 44-53-160 to provide that at least every 90 days, and in consultation with the South Carolina Law Enforcement Division, the board of pharmacy shall provide a written report to the Governor, the Attorney General, and the legislature outlining whether the board has identified any new chemical formulas that are used to make synthetic cannabinoids or cathinones not currently illegal under state law  - If any new chemical formulas are identified, the board shall immediately propose an emergency rule to add the new chemicals to the current list of formulas listed in state law and shall vote on the proposed rule as quickly as allowed  - The board, on its own initiative or under a written request from SLED, the DEA, or a poison control center, may adopt an emergency rule declaring a chemical formula to be a synthetic drug if the board finds that the chemical	5/5/2015 – Referred to Committee on Judiciary

SC HB 4123	formula: 1) has been scheduled by the DEA; 2) has been scheduled, emergency scheduled, or criminalized by another state; 3) has a high potential for abuse; and 4) has no accepted medical use in treatment in the US or lacks accepted safety for use in treatment under medical supervision  - In making its determination, the board shall consider the: 1) actual or relative potential for abuse; 2) scientific evidence of the substance's pharmacological effect, if known; 3) state of current scientific knowledge regarding the substance; 4) history and current pattern of abuse of the substance; 5) scope, duration, and significance of abuse of the substance; 6) degree of risk to the public health; and 7) psychological or physiological dependence liability of the substance  - Rule adopted is effective 30 days after adoption by the board and expires on the last legislative day of the following legislative session unless the substance is added as a controlled substance as otherwise allowed  Amends § 44-53-190, list of Schedule I substances, to add any other material, compound, mixture, or preparation that binds to the cannabinoid receptor or mimics the	5/5/2015 – Referred to Committee on
SD SB 61	pharmacological response of a Schedule I or II substance  Amends § 34-20B-14, list of Schedule I substances, to  amend class definitions and add substituted carboxylic acid  indoles	Judiciary  2/18/2015 – Signed by Governor; effective on signing
TN HB 287	Repeals and reenacts § 39-17-406, list of Schedule I substances, and includes 4-bromo-2,5-DMA, 2C-B, 25C-NBOMe, 25I-NBOMe, methylone, mephedrone, MDPV, 2C-E, 2C-D, 2C-C, 2C-I, 2C-T-2, 2C-T-4, 2C-H, 2C-N, 2C-P, UR-144, 5-fluoro-UR-144, APINACA, a-PBP, a-PVP, 3-FMC, 4-FMC, 4-MEC, 4-MePPP, naphyrone, pentedrone, pentylone, CP 47,497, cannabicyclohexanol, JWH-018, JWH-073, JWH-019, JWH-200, JWH-081, JWH-122, JWH-398, AM-2201, AM-694, RCS-4, RCS-8, JWH-203, AB-FUBINACA, ADB-PINACA, 5-fluoro-PB-22, PB-22	5/6/2015 – Companion bill became Pub. Ch. 302
TN HB 1173	- Amends § 39-17-438 to change class identifier from quinolinylindolecarboxesters to quinolinylindolecarboxylates	5/20/2015 – Companion bill became Pub. Ch. 401

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

TN SB 318	- Further amends § 39-17-438 to add the following class definitions: naphthoylindazoles, which includes THJ-2201, and methylindazolecarboxamidobutanoates, which includes AMB and fluoro-AMB  Repeals and reenacts § 39-17-406, list of Schedule I substances, and includes: 4-bromo-2,5-DMA, 2C-B, 25C-NBOMe, 25I-NBOMe, 25H-NBOMe, methylone, mephedrone, MDPV, 2C-E, 2C-D, 2C-C, 2C-I, 2C-T-2, 2C-T-4, 2C-H, 2C-N, 2C-P, UR-144, 5-fluoro-UR-144, APINACA, a-PBP, a-PVP, 3-FMC, 4-FMC, 4-MEC, 4-MePPP, naphyrone, pentedrone, pentylone, CP 47,497, cannabicyclohexanol, JWH-018, JWH-073, JWH-019, JWH-200, JWH-081, JWH-122, JWH-398, AM-2201, AM-694, RCS-4, RCS-8, JWH-203, AB-FUBINACA, ADB-PINACA, 5-fluoro-PB-22, PB-22, Kratom	5/6/2015 – Signed by Governor; effective 7/1/2015
TN SB 932	- Amends § 39-17-438 to change class identifier from quinolinylindolecarboxesters to quinolinylindolecarboxylates - Further amends § 39-17-438 to add the following class definitions: naphthoylindazoles, which includes THJ-2201; methylindazolecarboxamidobutanoates, which includes AMB and fluoro-AMB; naphthalenylindolecarboxylates, which includes NM-2201	5/8/2015 – Signed by Governor; effective 7/1/2015
TX HB 488	- Amends Health & Safety Code § 481.103, list of substances included in Penalty Group 2, to include 5-APB, 6-APB, 5-APDB, 6-APDB, 5-IT, 6-IT, BTCP, Bromo-Dragon-FLY, desoxypipradol, D2PM, MXE, 5-IAI, 5-MeO-DiPT, 5-MeO-DALT, PMMA, methoxyketamine, MDAI, 4-AcO-DMT, methedrone, - Amends Health & Safety Code § 481-1031, list of substances included in Penalty Group 2-A, to amend the class definitions and include a new class definition for benzoylindoles, which includes RCS-4, WIN 48,098	4/8/2015 – Left pending in committee
TX HB 595	- Amends Health & Safety Code § 481.1021, list of substances included in Penalty Group 1-A to include phenethylamines, which includes 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25P-NBOMe - Amends Health & Safety Code § 481.103, list of substances included in Penalty Group 2 to include pentedrone, 2C-B, 2C-C, 2C-D, 2C-E, 2C-I, 2C-N, 2C-P,	5/8/2015 – Laid on the table subject to call

		Г
	2C-T-2, 2C-T-4, 2C-T-7, aleph-2, DOB, DOC, DOET,	
	DOI, DOM, DON, DOIP, DOPR	
TX HB 597	- Amends Health & Safety Code § 481.1031, list of	5/8/2015 –
	substances included in Penalty Group 2-A, to amend class	Laid on the table
	definitions	subject to call
	- Further amends Health & Safety Code § 481.1031 to	
	include: AM-1220; naphthylindolecarboxamides, which	
	includes MN-24; RCS-8; benzoylindoles, which includes	
	AM-630, AM-679, AM-694, AM-1241, WIN 48,098,	
	RCS-4; adamantoylindoles, which includes AB-001, AM-	
	1248; adamantylindolecarboxamides, which includes	
	APICA, STS-135; adamantylindazolecarboxamides, which	
	includes 5-fluoro-AKB-48, AKB-48;	
	aminooxobutylindazolecarboxamide, which includes AB-	
	PINACA, AB-FUBINACA;	
	tetramethylcyclopropylindoles, which includes A-834,735,	
	A-796,260, AB-005, UR-144, 5-bromo-UR-144, 5-chloro-	
	UR-144, 5-fluoro-UR-144; tetramethylcyclopropane-	
	thiazole carboxamides, which includes A-836,339;	
	quinolinylindolecarboxylates, which includes BB-22, 5-	
	fluoro-PB-22, PB-22	
TX HB 2880	Amends Health & Safety Code § 481.103, list of	3/16/2015 -
	substances included in Penalty Group 2, to include 5-MeO-	Referred to
	aMT; APB; APDB; URB-597; HO-PCP; N-	Criminal
	methyltryptamine mimetic substances, including ACO-	Jurisprudence
	DMT, Baeocystine, BROMO-DALT, DiPT, DMT, DPT,	
	HO-DET, HO-DiPT, HO-DMT, HO-DPT, HO-MET,	
	MeO-DALT, MeO-DET, MeO-DiPT, MeO-DPT, MeO-	
	NMT, MET, NMT, norbufotenin; phencyclidine mimetic	
	substances, including amino-PCP, BCP, bromo-PCP,	
	BTCP, chloro-PCP, fluoro-PCP, HO-PCP, MeO-PCP,	
	methyl-PCP, nitro-PCP, OXO-PCP, PCE, PCM, PCPY,	
	TCP, TCPY; aminoindane mimetic substances, including	
	AMMI, IAI, MDAI, MMAI; fluoroamphetamine;	
	fluoromethamphetamine; methiopropamine; MXE;	
	methoxyketamine; MeO-PCP; a-PVT	
	- Amends Health & Safety Code § 481.1031, list of	
	substances included in Penalty Group 2-A, to include class	
	definitions for adamantoylindoles, which includes AB-001;	
	indazole-3-carboxamides, which includes AB-	
	FUBINACA, AB-PINACA, AKB-48, fluoro-AKB-48; 8-	
	Quinolinyl-indole-3-carboxylates, which includes fluoro-	
	PB-22, PB-22	
L	1	l .

TX HB 3889	Amends Health & Safety Code § 481.103, list of substances included in Penalty Group 2, to add MDMB-CHMINACA, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5fluoropentyl)-1H-indole-3-carboxamide, N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5fluoropentyl)-1H-indazole-3-carboxamide	3/23/2015 – Referred to Criminal Jurisprudence
TX SB 172	- Amends Health & Safety Code § 481.1021, list of substances included in Penalty Group 1-A to include phenethylamines, which includes 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25I-NBOMe, 25P-NBOMe - Amends Health & Safety Code § 481.103, list of substances included in Penalty Group 2 to include 5-APB; 6-APB; 5-APDB; 6-APDB; 5-IT; 6-IT; 5-MAPB; 6-MAPB; BTCP; Bromo-dragonFLY; desoxypipradrol; D2PM; MXE; 5-IAI; PMMA; 2-MeO-ketamine; MDAI; pentedrone; substituted tryptamines, which includes a-ET, a-MT, bufotenine, DET, DMT, 5-MeO-DiPT, 4-AcO-DMT, psilocin, psilocybin; 2,5-dimethoxyphenethylamines, which includes 2C-B, 2C-C, 2C-D, 2C-E, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7; 2,5-dimethoxyamphetamines, which includes aleph-2, aleph-4, DOB, DOC, DOET, DOI, DOM, DON, DOIP, DOPR	5/22/2015 – Signed by Governor; effective 9/1/2015
TX SB 173	- Amends Health & Safety Code § 481.1031, list of substances included in Penalty Group 2-A, to include definitions for "core component," which means any of the following: azaindole, benzimidazole, benzothiazole, carbazole, imidazole, indane, indazole, indene, indole, pyrazole, pyrazolopyridine, pyridine, or pyrrole; "group A component," which means any of the following: adamantane, benzene, cycloalkylmethyl, isoquinoline, methylpiperazine, naphthalene, phenyl, quinoline, tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, amino dimethyl oxobutane, amino phenyl oxopropane, methyl methoxy oxobutane, methoxy dimethyl oxobutane, methoxy phenyl oxopropane, or an amino acid; "link component," which means any of the following functional groups: carboxamide, carboxylate, hydrazide, methanone (ketone), ethanone, methanediyl (methylene bridge), or methine	5/22/2015 – Signed by Governor; effective 9/1/2015

	Front	
	- Further amends Health & Safety Code § 481.1031 to	
	provide that Penalty Group 2-A consists of any material,	
	compound, mixture, or preparation that contains any	
	quantity of a natural or synthetic chemical substance,	
	including its salts, isomers, and salts of isomers, listed by	
	name or contained within one of the structural classes	
	defined	
	- Amends Health & Safety Code § 481.1031 to delete most	
	of the currently listed substances and class definitions and	
	include: WIN 55,212-2; cyclohexylphenols, which the	
	addition of JWH-337, JWH-344; cannabinols;	
	tetramethylcyclopropyl thiazoles, which includes A-	
	836,339; any compound containing a core component	
	substituted at the 1-position to any extent, and substituted	
	at the 3-position with a link component attached to a group	
	A component, which includes naphthoylindanes,	
	naphthoylindazoles (THJ-018), naphthyl methyl indenes	
	(JWH-171), naphthoylindoles (JWH-018), quinolinoyl	
	·	
	pyrazole carboxylates (quinolinyl fluoropentyl	
	fluorophenyl pyrazole carboxylate), naphthoyl	
	pyrazolopyridines naphthoylpyrrole (JWH-030); any	
	compound containing a core component substituted at the	
	1-position to any extent, and substituted at the 2-position	
	with a link component attached to a group A component,	
	which includes naphthoylbenzimidazole (JWH-018	
	Benzimidazole), naphthoylimidazole; any compound	
	containing a core component substituted at the 3-position	
	to any extent, and substituted at the 2-position with a link	
	component attached to a group A component, which	
	includes naphthoyl benzothiazole; any compound	
	containing a core component substituted at the p-position	
	to any extent, and substituted at the 3-position with a link	
	component attached to a group A component, which	
	includes naphthoylcarbazole (EG-018)	
TX SB 199	- Amends Health & Safety Code § 481.103, list of	1/27/2015 -
	substances included in Penalty Group 2, to include 5-APB,	Referred to
	6-APB, 5-APDB, 6-APDB, 5-IT, 6-IT, BTCP, Bromo-	Criminal Justice
	Dragon-FLY, desoxypipradol, D2PM, MXE, 5-IAI, 5-	
	MeO-DiPT, 5-MeO-DALT, PMMA, methoxyketamine,	
	MDAI, 4-AcO-DMT, methodrone	
	- Amends Health & Safety Code § 481-1031, list of	
	substances included in Penalty Group 2-A, to amend the	
	substances included in Fenalty Oroup 2-A, to afficild the	

		T
	class definitions and include a new class definition for	
TTV CD 1500	benzoylindoles, which includes RCS-4, WIN 48,098	5/26/2015
TX SB 1583	- Creates Health and Safety Code § 481.038 which	5/26/2015 –
	provides that Schedule I includes any synthetic	Placed on general
	cannabinoid or cathinone designer drug that is not	state calendar
	regulated by the FDA or state law but that is similar by	
	structure or pharmacological effect to a Schedule I or II	
	substance that is regulated	
	- Defines "similar" to mean a substance that contains one	
	or more subunits in common with, or that mimics the	
	pharmacological effect of, a Schedule I or II substance	
	- Provides that any compound of a designer drug that is	
	manufactured, formulated, sold, distributed, or marketed	
	with the intent to circumvent the law is a Schedule I	
	substance	
	- Provides that examples of synthetic cannabinoid designer	
	drugs include substances that are generated using a three-	
	component pharmacophore model	
	- Provides that synthetic cannabinoid designer drugs that	
	contain one or more components of a controlled substance	
	in Schedule I or II under federal or state law are analogues	
TIA TID 1561	of Schedule I or II substances	4/15/0015
VA HB 1564	Amends § 54.1-3446, list of Schedule I substances, to add	4/15/2015 –
	dimethylone, THJ-2201, AB-CHMINACA, 5-fluoro-AB-	Governor's
	PINACA	recommendation
		adopted; effective
VA CD 1200	A 1 . 8 . 5 . 1 . 2 . 4 . 6 . 1 . 4 . 5 . 5 . 1 . 1 . 1	7/1/2015
VA SB 1380	Amends § 54.1-3446, list of Schedule I substances, to add	4/15/2015 —
	dimethylone, THJ-2201, AB-CHMINACA, 5-fluoro-AB-	Governor's
	PINACA	recommendation
		adopted; effective 7/1/2015
MA IID	Creates new sections that may ide that it is an unfair or	
WA HB	- Creates new sections that provide that it is an unfair or	6/30/2015 —
<b>2136</b>	deceptive trade practice to distribute, dispense,	Signed by
	manufacture, display for sale, offer for sale, attempt to sell,	Governor; effective 7/1/2015
	or sell to a purchaser any product that contains any amount	effective 7/1/2013
	of any synthetic cannabinoid or cathinone or methcathinone	
	- Amends § 69.50.204, list of Schedule I substances, to add	
	tetrahydrocannabinols that have been chemically	
	synthesized and have either been demonstrated to have	
	binding activity at one or more cannabinoid receptors or is	
	a chemical analog or isomer of a compound that has been	

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	domonstrated to have hinding activity at any arms	
	demonstrated to have binding activity at one or more	
	cannabinoid receptors	
	- Creates new penalties for the distribution, dispensing,	
	manufacture, display for sale, offer for sale, attempt to sell,	
	or sale of any product that contains a synthetic	
	cannabinoid, cathinone, or methcathinone to a purchaser,	
	with increased fines for purchasers under the age of 18	
WA SB 5434	Amends § 69.50.204, list of Schedule I substances, to add	6/28/2015 —
	naphthoylindoles, naphthylmethylindoles,	By resolution,
	naphthoylpyrroles, naphthylmethylindenes,	reintroduced and
	phenylacetylindoles, cyclohexylphenols, benzoylindoles,	retained in
	WIN 55,212-2, HU-210	present status
WA SB 5673	- Creates new section that provides it is unlawful for any	6/28/2015 -
	person to distribute, dispense, manufacture, display for	By resolution,
	sale, offer for sale, attempt to sell, or sell any product that	reintroduced and
	contains any amount of any synthetic cannabinoid,	retained in
	cathinone, or methcathinone	present status
	- Amends § 69.50.204, list of Schedule I substances, to add	F
	tetrahydrocannabinols that have been chemically	
	synthesized and have either been demonstrated to have	
	binding activity at one or more cannabinoid receptors or is	
	a chemical analog or isomer of a compound that has been	
	demonstrated to have binding activity at one or more	
	cannabinoid receptors	
WA SB 6136	- Creates new section that provides that it is an unfair or	6/28/2015 –
WA 3D 0130		
	deceptive trade practice to distribute, dispense,	By resolution,
	manufacture, display for sale, offer for sale, attempt to sell,	reintroduced and
	or sell to a purchaser any product that contains any amount	retained in
	of any synthetic cannabinoid or cathinone or	present status
	methcathinone	
	- Amends § 69.50.204, list of Schedule I substances, to add	
	tetrahydrocannabinols that have been chemically	
	synthesized and have either been demonstrated to have	
	binding activity at one or more cannabinoid receptors or is	
	a chemical analog or isomer of a compound that has been	
	demonstrated to have binding activity at one or more	
	cannabinoid receptors	
WV HB	- Amends § 60A-2-204, list of Schedule I substances, to	<mark>4/2/2015 —</mark>
<mark>2931</mark>	add 25B-NBOMe, 25C-NBOMe, 25I-NBOMe, 5-MeO-	Approved by
	MiPT, 4-HO-DiPT, 4-HO-MiPT, 4-HO-MET, 4-AcO-	Governor;
	DiPT, 5-MeO-AMT, 4-MeO-DMT, 4-HO-DET, 5-MeO-	effective
	DALT, 4-AcO-DMT, 4-HO-DET	<mark>6/10/2015</mark>

WY SF 16	Amends § 35-7-1014, list of Schedule I substances, to include AB-CHMINACA, THJ-2201, BB-22, ethylone, 4-MEC, 4-MePPP, a-PVP, butylone, pentedrone, pentylone, naphyrone, a-PBP	3/6/2015 – Signed by Governor; effective on signing
Regulation No.	Description	Status
79 FR 75767-01 (21 CFR 1308)	Amends list of Schedule I substances to temporarily schedule AB-CHMINACA, AB-PINACA, THJ-2201	12/19/2014 – Proposed rules
80 FR 5042- 01 (21 CFR 1308)	Amends list of Schedule I substances to temporarily schedule AB-CHMINACA, AB-PINACA, THJ-2201	1/30/2015 — Final order
80 FR 27611-01 (21 CFR 1308)	Amends list of Schedule I substances to temporarily schedule UR-144, 5-fluoro-UR-144, APINACA	5/14/2015 – Proposed rules
80 FR 27854-01 (21 CFR 1308)	Amends list of Schedule I substances to temporarily schedule UR-144, 5-fluoro-UR-144, APINACA	5/15/2015 – Final order
80 FR 55565-01 (21 CFR 1308)	Amends list of Schedule I substances to temporarily schedule ADB-CHMINACA	9/16/2015 – Proposed rules
AL 386549 (ADC 420-7-2, App. 1)	Amends list of Schedule I substances to include AB-CHMINACA, AB-PINACA, THJ-2201	2/27/2015 – Proposed rules
AL 408667 (ADC 420-7-2, App. 1)	Amends list of Schedule I substances to include AB-CHMINACA, NM-2201, AB-PINACA	10/30/2015 – Proposed rules
AR 387375 (ADC 007.07.2)	Amends list of Schedule I substances to add butylone, MAB-CHMINACA	3/19/2015 – Proposed regulations
AR 401886 (ADC 007.07.2)	Amends list of Schedule I substances to add Kratom, a-PVP	8/31/2015 – Proposed regulations
DC 358978 (17 ADC Ch. 9)	- Creates Title 17, Chapter 9, Prohibition on the Sale of Synthetic Drugs, which provides that no person doing business in DC that has or is required to have a business license issued by law shall sell, offer for sale, allow the sale of, display for sale, possess, market, trade, barter, give, devise, or otherwise make or attempt to make available: 1) synthetic drugs; 2) products packaged as non-consumable products which contain warning notices or age restrictions not typically found on products marketed for that purpose,	11/28/2014 – Adopted; effective 11/28/2014

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

for example, potpourri, incense, or bath salt packages that bear a warning label including, but not limited to, "not for purchase by minors," "manufacturer and retailer are not responsible for misuse of this product," "not for human consumption," or "must be 18 years or older to purchase"; 3) products containing notices on the packaging not typically found on products marketed for that purpose, for example, potpourri or shoe oil containing notices such as "legal in 50 states," "100% legal blend," "does not contain any chemical compounds prohibited by law," "contains no prohibited chemicals," "product is in accordance with State and Federal laws," "legal herbal substance," "100% chemical free," "100% synthetic free"; statute includes exemptions

- Allows an investigator or inspector to enter and inspect the premises during regular business hours to determine whether the business is in compliance
- Any reasonable evidence may be used to demonstrate that a product's marketed and/or intended use causes it to fit the definition of a synthetic drug including, but not limited to, any of the following evidentiary factors: 1) the product is not suitable for its marketed use (such as a crystalline or powder product being marketed as "glass cleaner"); 2) the individual or business providing, distributing, displaying, or selling the product does not typically provide, distribute, or sell products that are used for the product's marketed use (such as liquor stores, smoke shops, or gas/ convenience stores selling "plant food"); 3) the product contains a warning that is not typically present on products that are used for the product's marketed use including, but not limited to, "not for human consumption," "not for purchase by minors," "must be 18 years or older to purchase," "100% legal blend"; 4) the product is significantly more expensive than products that are used for the product's marketed use, such as 0.5 grams of a substance marketed as "glass cleaner" costing \$50.00, 1 gram of potpourri costing \$10.00, or 0.5 grams of incense costing \$15.00; 5) the product resembles an illicit street drug; 6) the business licensee or employee has been warned by DCRA or received a criminal incident report, arrest report, or equivalent from any law enforcement agency that the product or a similarly labeled product contains a synthetic drug

Yellow highlighted text indicates the legislation has been enacted into law

		T
	- Any business licensee violating this chapter may receive a Notice of Infraction or the DCRA may issue a notice of intent to suspend or revoke the licensee's business license; following an adverse adjudication, the DCRA shall suspend or revoke the business license	
GA 379768 (ADC 480- 3404)	Amends list of synthetic cannabinoids to include FUB-144, NM2201	12/18/2014 – Filed regulations Effective 12/16/2014
IL 385994 (77 ADC 2070.117, .118, .389)	Amends regulations to comply with amendments to 21 CFR 1308 that added three synthetic cannabinoids to Schedule I	2/27/2015 – Peremptory rules
IN 392810 (856 IAC 2- 2-2)	Amends list of Schedule I substances to add PB-22, 5-fluoro-PB-22, BCP, 25B-NBOMe, APB, AB-PINACA, AB-FUBINACA, fluoro-ADBICA, APDB, THJ-2201, AM-2201, MN-25, FUB-PB-22, FDU-PB-22, 5-fluoro-AB-PINACA, 4-MePPP, a-PBP, AB-CHMINACA	5/27/2015 – Emergency rules Effective 6/18/2015
IA 411397 (ADC 657- 10.38)	Amends regulation to add AB-CHMINACA, AB-PINACA, THJ-2201 to list of temporarily designated controlled substances	12/9/2015 – Notices of intended action
KY 410855 (902 KAR 55:015)	- Amends regulation to add 25H-NBOMe, 25I-NBOMe, 25B-NBOMe, 25C-NBOMe, PMMA, PMA, THJ-2201, THJ-018, FUBIMINA - Further amends regulation to add class definitions for: indole-3-carboxylate esters, which includes PB-22, 5F-PB-22; and indazole-3-carboxamides, which includes AB-FUBINACA, AB-CHMINACA	12/1/2015 – Proposed amendments
NV 379682 (ADC 453.510)	Amends list of Schedule I substances to add AB-CHMINACA, dimethylone, ethylone, THJ-2201, AB-PINACA, APICA, class definition of tetrahydrocannabinols	7/30/2015 – LCB drafts
NV 403491 (ADC 453.510)	Amends list of Schedule I substances to add AB-CHMINACA, THJ-2201, AB-PINACA, APICA, dimethylone, ethylone, class definition of tetrahydrocannabinols	9/15/2015 – Initial drafts
NM 398795 (ADC 16.19.20)	Amends 16.19.20, list of Schedule I substances, to include 2C-B, N-hydroxy-MDA, 5-MeO-DMT, mephedrone, MDPV, 2C-E, 2C-D, 2C-T-2, 2C-T-4, 2C-H, 2C-N, 2C-P, methylone, PB-22, 5-fluoro-PB-22, AB-FUBINACA, ADB-PINACA, pentedrone, 4-FMC, 3-FMC, AB-CHMINACA, AB-PINACA, THJ-2201, 3-MMC, 3,4-DMMC, 3-MEC, 4-MeBP, 4-MTA, 5-Me-MDA, 6-APB,	11/30/2015 – Adopted rules and regulations Effective 12/13/2015

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

		T
	PMA, 2C-B, 2C-C, 2C-D, 2C-E, 2C-G, 2C-I, 2C-T21, 2C-	
	B-FLY, Bromo-DragonFLY, DOB, DOC, DOM, TMA2,	
	TMA6, MDAT, 4-acetoxy DiPT, 4-acetoxy DMT, 4-HO-	
	MET, 4-HO-MiPT, 5-MeO-aMT, 5-MeO-MiPT, DiPT,	
	DPT, 5-MeO-DALT, 3-MeO-PCP, 4-MeO-PCP, MK-801,	
	PCE, methoxetamine, PCPr, tenocyclidine, 3-MeO-PCE,	
	ETHLAD, AL-LAD, PRO-LAD, DBZP, MBZP, mCPP,	
	MDBZP, meOPP, pCPP, pFPP, 2-DPMP, D2PM, HDMP-	
	28, nocaine, BTQ	
NY 400997	Amends list of explicitly prohibited synthetic cannabinoids	11/25/2015 -
(10 NYCRR	to include JWH-007; JWH-098; JWH-164; MAM-2201;	Emergency
9.1)	EAM-2201; JWH-201; AM-2233; adamantoylindazoles,	rulemakings
9.1)	which includes AKB-48, MAB-CHMINACA, 5F-AKB-	Effective
	48; tetramethylcyclopropylcarbonylindoles, which includes	11/4/2015
OH 407000	UR-11, XLR-11, A-796,260	11/17/2015
OH 407088	- Amends 4729-11-02 to change language from "any	11/17/2015 –
(ADC 4729-	synthetic cannabinoid" and "any synthetic cathinone" to	Revised filings
11-02)	"any compound"	
	- Further provides a class definition for fentanyl	
	compounds and designates them as Schedule I substances	
TX 387497	Amends list of Schedule I substances to include PB-22,	3/20/2015 -
(uncodified)	AB-FUBINACA, ADB-PINACA, 4-MEC, 4-MePPP, a-	In addition
	PVP, butylone, pentedrone, pentylone, 4-FMC, 3-FMC,	
	naphyrone, a-PBP	
TX 388496	Amends list of Schedule I substances to include AB-	4/3/2015 -
(uncodified)	CHMINACA, AB-PINACA, THJ-2201	In addition
VA 396373	Amends list of Schedule I substances to include ADB-	7/13/2015 –
(18 VAC	CHMINACA, 5-fluoro-AMB, NM-2201, FUB-144, 4-	Final regulations
110-20-322)	BMC, 4-CMC	Effective Effective
110 20 322)	birie, i chie	8/12/2015
VT 394841	- Amends 12-5-23:4.0, list of stimulant drugs, to add 2-AI,	6/16/2015 –
(ADC 12-5-	2-MMC, MDMA, 4-BMC, 4-CMC, 4-MPD, 5-IAI, a-	Proposed rules
23:4.0, 7.0)	ethylaminopentiophenone, bk-2C, dimethylone, MBPV,	1 Toposcu Tutes
23.4.0, 7.0)		
	MTA, MT-45, NM2AI, pyrovalerone	
	- Amends 12-5-23:7.0, list of hallucinogenic drugs, to add	
	MEXP, 5-EAPB, 5F-AMB, 5F-ADBICA, 5F-AKB-48, 5F-	
	MN-018, 5F-MN24, 5F-SDB-005, 5F-THJ-2201, 5FAB-	
	FUBINACA, 5F-AB-PINACA, 5-fluoro-PB-22, 5-fluoro-	
	SDB-006, 5-IT, 5-MAPB, 5-MeO-MDA, AB-	
	CHMINACA, AB-PINACA, ACEA, ACPA, ADBICA,	
	AL-LAD, AM-630, AM-4113, ASDB-FUB-187, EAM-	
	2201, EG-018, FDU-PB-22, FAB-144, F-UPB-22, FUB-	
	AKB-48, FUB-PB-22, FUBIMINA, HDMP-28, L-	
	1313D 10, 1 0D 1 D 22, 1 0DHVIII 1/1, 11DIVII -20, L-	l

<sup>© 2015</sup> Research is current as of December 11, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

	759,633, L-759,656, LSZ, MA-CHMINICA, MDMB-	
	CHMINICA, mepirapim, MMB-2201, MMB-	
	CHMINACA, MN-18, MN-23, Kratom, NM-2201, SDB-	
	005, SR 144528, STS-144, THJ-018, THJ-2201, W-15	
WY 410271	Amends list of Schedule I substances to include 5F-AMB,	11/26/2015 —
(ADC ATTG	ADB-FUBINACA	Emergency rules
SICS Ch. 1,		<b>Effective</b>
§ 4)		11/16/2015